FHFangfang Hu

Fangfang Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fangfang Hu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and Multicohort Validation of a Personalized Survival Prediction Model for ALS: Benchmarking Against the ENCALS Reference Model

    by Jiaoting Jin, Xing Qin, Tingge Zhu, Qiuli Zhang, Xia He, Fenying Chen, Yanfei Cheng, Rui Jia, Li Kang, Zhiting Sun, et al.

    Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by phenotypic heterogeneity; personalized survival prediction remains limited in Asians. Leading models such as ENCALS were derived mainly from European cohorts and rely on ethnically variable biomarkers (e.g., C9orf72 repeat expansion), limiting their use where genetic testing is not routine. Methods: We conducted a retrospective cohort study at two Chinese centers. A derivation cohort (n=532, 2010–2020) and temporal validation cohort (n=300, 2021–2024) supported development and temporal validation; an independent external cohort (n=126) from a separate center provided external validation. Cox proportional hazards were violated, we fit a lognormal accelerated failure-time model on MICE-imputed data. The nomogram was evaluated by IPCW-adjusted time-dependent AUC (td-AUC), calibration, and DCA, and benchmarked head-to-head against recalibrated ENCALS on same cohorts. Findings: Seven independent predictors were identified: age at onset, sex, diagnostic delay, ALSFRS-R, onset-to-second-region interval, region of onset, and Awaji-Shima criteria. The nomogram showed stable discrimination (bootstrap IPCW-td-AUC 0.844 - 0.892 derivation, 0.848 - 0.878 temporal, 0.845 - 0.905 external). Calibration was good in derivation/external (IPCW slopes≈1.0) but drifted temporally. DCA indicated favorable net benefit. Against recalibrated ENCALS model, the nomogram showed comparable discrimination in temporal cohort (Δ td-AUC −0.020 to +0.008 at 1–3-year) and numerically higher discrimination at 3–5-year externally, although based on few at-risk patients, with better overall calibration (Cox–LP slope 1.017 vs 0.867). Interpertation: We developed and externally validated an ALS prognostic nomogram using seven routinely collected clinical variables across all phenotypic spectrum for survival estimation. Benchmarked head-to-head against recalibrated ENCALS, it showed comparable discrimination at 1–3-year and numerically higher discrimination with better calibration at 3–5-year, supporting its use where routine genotyping is unavailable. The model is deployed as a free online calculator. External validation across ethnically diverse populations is a priority.

  • Open Access

    Personalised Prognostic Prediction for Amyotrophic Lateral Sclerosis Patients Based on Real-world Data: A Model Development and Validation Study

    by Jiaoting Jin, Xing Qin, Qiuli Zhang, Xia He, Yanfei Cheng, Rui Jia, Li Kang, Xiao Liu, Lingwei Wang, Jingxia Dang, et al.

    Background: Existing ALS prognostic models rely on biomarkers with marked ethnic variability and provide risk categories rather than individualised probabilities, limiting their generalisability across populations and full ALS phenotype spectrum. Methods: We conducted a retrospective cohort study of 833 patients enrolled at First Affiliated Hospital of Xi'an Jiaotong University. The training cohort included 532 patients (2010–2020), and the temporal external validation cohort included 301 patients (2021–2024). Prognostic factors were identified by Parametric Survival Model. A nomogram was constructed and validated through internal bootstrapping and external validation. Model performance was assessed by area under the receiver operating characteristic curve (AUC), calibration, and decision curve analysis (DCA). Findings: Seven independent prognostic factors were identified: age of onset, sex, diagnostic delay time, ALSFRS-R, interval time onset-second involvement region, region of onset, and Awaji-Shima Criteria. The nomogram showed excellent discrimination (internal validation AUC: 0.871 for 3-year and 0.833 for 5-year; external validation AUC: 0.848 for 3-year), strong calibration, and net clinical benefit on DCA. Interpretation: This nomogram, covering all ALS phenotypes in a Chinese cohort, demonstrated discrimination nominally higher than the landmark van den Berg model (3-year AUC 0.848 vs 0.78) using seven routine variables without genetic or biomarker data. Individualised risk estimates may enable patient stratification in clinical trials, where phenotypic heterogeneity contributes to failures beyond ALSFRS-R slope. Multicenter validation across diverse populations is warranted.

  • Acute nitrous oxide‐induced neuropathy mimicking Guillain‐Barré syndrome

    by Xing Qin, Li Kang, Xiao Liu, Jiaoting Jin, Fangfang Hu, Wenhui Lu, Yongning Deng, Qiao Yi Chen, Jingxia Dang

    The early clinical features of nitrous oxide (N2O)‐induced neuropathy were mimicking that of Guillain‐Barré syndrome (GBS). We aimed to explore clinical and laboratory characteristics of N2O‐induced neuropathy in comparison with GBS. We retrospectively reviewed data of 15 patients with N2O‐induced neuropathy and compared them with 15 GBS patients. The age of the N2O‐induced neuropathy group was significantly younger than that in the GBS group (22 ± 5 vs 45 ± 17). Paresthesia was more common in N2O‐induced neuropathy group (100% vs 53.3%). The proportion of distal upper limbs weakness was lower than that in GBS group (20.0% vs 93.3%). There was no significant difference in the distal weakness of the lower limbs (100% vs 80.0%). The incidence of motor conduction block and compound muscle action potential amplitude reduction in upper limbs was lower than that in GBS group (6.7% vs 60.0%; 26.7% vs 80.0%). The sensory nerve action potential amplitude drop in the lower limbs was more severe than that in GBS group (53.3% vs 0). The increase of Mean corpuscular volume (MCV) was more pronounced compared to GBS group (96.97 ± 6.00 vs 88.55 ± 5.41). High homocysteine levels were more common in N2O‐related group [29.80(11.60, 70.50) vs 14.35(9.22, 19.30)]. Typical clinical features of the acute N2O neuropathy appears to be a myeloneuropathy, affecting the lower limbs more than the upper limbs, mixed axonal‐demyelinating electrophysiological performance, higher homocysteine level, and larger MCV and common posterior spinal cord involvement in cervical segment.


  • Open Access

    Comparative assessment of blood Metal/metalloid levels, clinical heterogeneity, and disease severity in amyotrophic lateral sclerosis patients

    by Xing Qin, Peng Wu, Ting Wen, Rui Jia, Ronghua Zhang, Jiaoting Jin, Fangfang Hu, Qiao Yi Chen, Jingxia Dang


  • Open Access

    Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort

    by Rui Jia, Stephanie Shepheard, Jiaoting Jin, Fangfang Hu, Xing Zhao, Li Xue, Li Xiang, Huaguang Qi, Qiumin Qu, Feng Guo, et al.

    To comprehensively assess whether p75ECD in urine could be a candidate biomarker for ALS evaluation. Urine samples were collected from 101 ALS patients, 108 patients with other neurological disease (OND) and 97 healthy controls. 61 ALS patients were followed up with clinical data including ALSFRS-r every 6 to 12 months, 23 ALS patients died and 17 ALS patients lost touch during follow up period. Enzyme-linked immunoassay was employed to determine urine p75ECD concentration. The ALSFRS-r was employed to assess the severity of ALS. The concentration of p75ECD in ALS was significantly higher than that of OND and CTRL (p < 0.001). Additionally, urine p75ECD concentrations in ALS-definite grade patients were significantly higher than that in ALS-probable grade and ALS-possible grade patients (p < 0.001). Higher urine p75ECD concentrations were correlated with increased clinical stage (p = 0.0309); urine p75ECD concentrations and ALSFRS-r were negatively correlated (p = 0.022); and urine p75ECD concentration in the fast-progressing ALS group was significantly higher than that in slow-progression (p = 0.0026). Our finding indicates that urine p75ECD concentration provides additional evidence for patients with clinically suspected ALS, and can be employed to evaluate ALS-severity.